Global Drug Delivery Partnering Deal Trends, Players and Financials 2014-2019 – ResearchAndMarkets.com


Drug Delivery Partnering 2014-2019: Deal Trends, Players and Financials”

report has been added to ResearchAndMarkets.com’s

The Global Drug Delivery Partnering 2014-2019 report provides
comprehensive understanding and unprecedented access to the drug
delivery partnering deals and agreements entered into by the world’s
leading healthcare companies.

The report takes the reader through a comprehensive review Drug Delivery
deal trends, key players, top deal values, as well as deal financials,
allowing the understanding of how, why and under what terms, companies
are entering Drug Delivery partnering deals.

The report presents financial deal term values for Drug Delivery deals,
listing by headline value, upfront payments, milestone payments and
royalties, enabling readers to analyse and benchmark the financial value
of deals.

The middle section of the report explores the leading dealmakers in the
Drug Delivery partnering field; both the leading deal values and most
active Drug Delivery dealmaker companies are reported allowing the
reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 850 online deal
records of actual Drug Delivery deals, as disclosed by the deal parties,
are included towards the end of the report in a directory format – by
company A-Z, stage of development, deal type, therapy focus, and
technology type – that is easy to reference. Each deal record in the
report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as
submitted to the Securities Exchange Commission by companies and their
partners. Whilst many companies will be seeking details of the payment
clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases
and databases do not.

The initial chapters of this report provide an orientation of
Drug Delivery dealmaking.

  • Chapter 1 provides an introduction to the report, whilst chapter 2
    provides an overview of the trends in Drug Delivery dealmaking since
    2014, including details of headline, upfront, milestone and royalty
  • Chapter 3 provides a review of the leading Drug Delivery deals since
    2014. Deals are listed by headline value. Where the deal has an
    agreement contract published at the SEC a link provides online access
    to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active
    companies in Drug Delivery dealmaking with a brief summary followed by
    a comprehensive listing of Drug Delivery deals announced by that
    company, as well as contract documents, where available.
  • Chapter 5 provides a comprehensive and detailed review of Drug
    Delivery partnering deals signed and announced since Jan 2014, where a
    contract document is available in the public domain. Each deal title
    links via Weblink to an online version of the deal record and contract
    document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Drug
    Delivery partnering deals signed and announced since Jan 2014. The
    chapter is organized by specific Drug Delivery technology type. Each
    deal title links via Weblink to an online version of the deal record
    and where available, the contract document, providing easy access to
    each deal on demand.

A comprehensive series of appendices is provided organized by Drug
Delivery partnering company A-Z, stage of development, deal type, and
therapy focus. Each deal title links via Weblink to an online version of
the deal record and where available, the contract document, providing
easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the
trends and activities in Drug Delivery partnering and dealmaking since

In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of Drug Delivery technologies and products.

Key benefits

  • In-depth understanding of Drug Delivery deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Drug Delivery agreements with numerous
    real life case studies
  • Detailed access to actual Drug Delivery contracts entered into by
    leading biopharma companies
  • Identify most active Drug Delivery dealmakers since 2014
  • Insight into terms included in a Drug Delivery partnering agreement,
    with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal
    terms for partner companies

Key Topics Covered:

1. Introduction

2. Trends in Drug Delivery dealmaking

2.1. Introduction

2.2. Drug Delivery partnering over the years

2.3. Most active Drug Delivery dealmakers

2.4. Drug Delivery partnering by deal type

2.5. Drug Delivery partnering by therapy area

2.6. Deal terms for Drug Delivery partnering

2.6.1 Drug Delivery partnering headline values

2.6.2 Drug Delivery deal upfront payments

2.6.3 Drug Delivery deal milestone payments

2.6.4 Drug Delivery royalty rates

3. Leading Drug Delivery deals

3.1. Introduction

3.2. Top Drug Delivery deals by value

4. Most active Drug Delivery dealmakers

4.1. Introduction

4.2. Most active Drug Delivery dealmakers

4.3. Most active Drug Delivery partnering company profiles

5. Drug Delivery contracts dealmaking directory

5.1. Introduction

5.2. Drug Delivery contracts dealmaking directory

6. Drug Delivery dealmaking by technology type

7. Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking


Appendix 1 – Drug Delivery deals by company A-Z

Appendix 2 – Drug Delivery deals by stage of development

Appendix 3 – Drug Delivery deals by deal type

Appendix 4 – Drug Delivery deals by therapy area

Appendix 5 – Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/79ldcp


Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Drug


I have been involved with publishing and marketing for the past 37 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.For people who love to save money and earn while saving, there is a new program called the r network. You are provided with a card that entitles the user to automatic savings on more than 300,000 products. Learn more about the revv card today. This is by invitation only to be some of the first people to get this card.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.

You May Also Like